^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.
Published date:
05/16/2018
Excerpt:
EGF104900 randomized 296 women with HER2+ advanced BC who experienced progression on prior T-containing regimens to receive either L alone or L+T….Median PFS of the HER2-E/ERBB2H group was 3.5 months (2.6-54) compared to 1.2 months (1-1.7) in others. The ORR and CBR of the HER2-E/ERBB2H group were higher compared to others (ORR 16.25% vs. 3.66%; p = 0.017 and CBR 66.25% vs. 26.83%; P < 0.001).
DOI:
10.1200/JCO.2018.36.15_suppl.1025
Trial ID:
Excerpt:
Tyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2):...in combination with trastuzumab for patients with hormone-receptor-negative metastatic disease that has progressed on prior trastuzumab therapy or therapies in combination with chemotherapy...
Source:
Title:
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
Excerpt:
...Documented amplification of the ErbB2 gene by fluorescence in situ hybridization (FISH) or documented overexpression of the ErbB2 protein by IHC in primary or metastatic tumor tissue...
Trial ID:
